Abstract
Epigenetic alterations produce heritable changes in phenotype or gene expression without changing DNA sequence. Modified levels of gene expression contribute to a variety of human diseases encompassing genetic disorders, pediatric syndromes, autoimmune disease, aging, and cancer. Alterations in proprotein convertase gene expression are associated with numerous disease states; however, the underlying mechanism for changes in PC gene expression remains understudied. Epigenetic changes in gene expression profiles can be accomplished through modification of chromatin, specifically via chemical modification of DNA bases (methylation of cytosine) or associated histone proteins (acetylation or methylation). In general, active chromatin is associated with low DNA methylation status and histone acetylation, whereas silenced gene are typically in inactive regions of chromatin exhibiting DNA hypermethylation and histone deacetylation. This chapter will provide in-depth protocols to analyze epigenetic alterations in proprotein convertase gene expression using the PCSK6 gene in the context of human ovarian cancer as a model system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jones, P. A., and Baylin, S. B. (2007) The epigenomics of cancer Cell 128, 683–92.
Lopez, J., Percharde, M., Coley, H. M., Webb, A., and Crook, T. (2009) The context and potential of epigenetics in oncology Br J Cancer 100, 571–7.
Balch, C., Fang, F., Matei, D. E., Huang, T. H., and Nephew, K. P. (2009) Minireview: Epigenetic changes in ovarian cancer Endocrinology 150, 4003–11.
Feinberg, A. P. (2007) Phenotypic plasticity and the epigenetics of human disease Nature 447, 433–40.
Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex Nature 393, 386–9.
Jones, P. L., Veenstra, G. J., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and Wolffe, A. P. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription Nat Genet 19, 187–91.
Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, D. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation Genes Dev 13, 1924–35.
Harikrishnan, K. N., Chow, M. Z., Baker, E. K., Pal, S., Bassal, S., Brasacchio, D., Wang, L., Craig, J. M., Jones, P. L., Sif, S., and El-Osta, A. (2005) Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing Nat Genet 37, 254–64.
Szyf, M. (2009) Epigenetics, DNA methylation, and chromatin modifying drugs Annu Rev Pharmacol Toxicol 49, 243–63.
Bassi, D. E., Mahloogi, H., and Klein-Szanto, A. J. (2000) The proprotein convertases furin and PACE4 play a significant role in tumor progression Mol Carcinog 28, 63–9.
Bassi, D. E., Fu, J., Lopez de Cicco, R., and Klein-Szanto, A. J. (2005) Proprotein convertases: “master switches” in the regulation of tumor growth and progression Mol Carcinog 44, 151–61.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., and Thun, M. J. (2008) Cancer statistics CA Cancer J Clin 58, 71–96.
Scully, R. E., Young, R. H., and Clement, P. B. (1996) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In Atlas of Tumor Biology, ed. Rosai, J. Washington, DC: Armed Forces Institute of Pathology.
Scully, R. E. (1995) Pathology of ovarian cancer precursors J Cell Biochem Suppl 23, 208–18.
Horiuchi, A., Itoh, K., Shimizu, M., Nakai, I., Yamazaki, T., Kimura, K., Suzuki, A., Shiozawa, I., Ueda, N., and Konishi, I. (2003) Toward understanding the natural history of ovarian carcinoma development: A clinicopathological approach Gynecol Oncol 88, 309–17.
Dubeau, L. (1999) The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol Oncol 72, 437–42.
Auersperg, N., Wong, A. S., Choi, K. C., Kang, S. K., and Leung, P. C. (2001) Ovarian surface epithelium: Biology, endocrinology, and pathology Endocr Rev 22, 255–88.
Fathalla, M. F. (1971) Incessant ovulation–a factor in ovarian neoplasia? Lancet 2, 163.
Fu, Y., Campbell, E. J., Shepherd, T. G., and Nachtigal, M. W. (2003) Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells Mol Cancer Res 1, 569–76.
Ammerpohl, O., Martin-Subero, J. I., Richter, J., Vater, I., and Siebert, R. (2009) Hunting for the 5th base: Techniques for analyzing DNA methylation Biochim Biophys Acta 1790, 847–62.
Clark, S. J., Statham, A., Stirzaker, C., Molloy, P. L., and Frommer, M. (2006) DNA methylation: Bisulphite modification and analysis Nat Protoc 1, 2353–64.
Clark, S. J., Harrison, J., Paul, C. L., and Frommer, M. (1994) High sensitivity mapping of methylated cytosines Nucleic Acids Res 22, 2990–7.
Wu, J. C., and Santi, D. V. (1985) On the mechanism and inhibition of DNA cytosine methyltransferases Prog Clin Biol Res 198, 119–29.
Sheikhnejad, G., Brank, A., Christman, J. K., Goddard, A., Alvarez, E., Ford, H., Jr., Marquez, V. E., Marasco, C. J., Sufrin, J. R., O‘Gara, M., and Cheng, X. (1999) Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5, 6-dihydro-5-azacytosine J Mol Biol 285, 2021–34.
Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006) Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5, 769–84.
Shepherd, T. G., Theriault, B. L., Campbell, E. J., and Nachtigal, M. W. (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients Nat Protoc 1, 2643–9.
Grunau, C., Clark, S. J., and Rosenthal, A. (2001) Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters Nucleic Acids Res 29, E65–5.
Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93, 9821–6.
Hon, G. C., Hawkins, R. D., and Ren, B. (2009) Predictive chromatin signatures in the mammalian genome Hum Mol Genet 18, R195–201.
Park, P. J. (2009) ChIP-seq: Advantages and challenges of a maturing technology Nat Rev Genet 10, 669–80.
Acknowledgments
This work was supported by funds to MWN from the Canadian Institute of Health Research regional partnership grant program (ROP-91758) partnered with the Nova Scotia Health Research Foundation (MED-Matching-2008-4881) and the Dalhousie Cancer Research Program.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Fu, Y., Nachtigal, M.W. (2011). Analysis of Epigenetic Alterations to Proprotein Convertase Genes in Disease. In: Mbikay, M., Seidah, N. (eds) Proprotein Convertases. Methods in Molecular Biology, vol 768. Humana Press. https://doi.org/10.1007/978-1-61779-204-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-61779-204-5_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-203-8
Online ISBN: 978-1-61779-204-5
eBook Packages: Springer Protocols